BioCentury This Week

Ep. 354 - East-West Summit Takeaways

• BioCentury • Season 7 • Episode 354

Share episode

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 26:21

Biotechs in South Korea and other regions of Asia outside of China need to lean into innovation to distinguish themselves from their Chinese counterparts. On a special edition of the BioCentury This Week podcast, BioCentury’s analysts are joined by industry guests Ya-Ting Lei and Luther (Ruizhe) Zhao to discuss why the best path for biotechs in Korea and Japan is to lean into target, biology and modality risk, as well as other takeaways from the fifth BioCentury-BayHelix Biopharma Summit, which ran March 9-12 in Seoul and Daejeon, South Korea.
Lei is director of BD Asia at Merck KGaA, and Zhao is VP, China clinical analytics at Caidya.

View full story: https://www.biocentury.com/article/658776

#AsiaBiotech #SouthKoreaBiotech #BiopharmaSummit #BiotechInnovation #DrugDevelopmentStrategy

00:00 - Introduction
02:32 - Key Takeaways
05:46 - Faster Trials, Better Data
08:19 - Global Diligence, Local Success
15:13 - Cross Border Synergies
17:34 - Korean Biotech

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text

[AI-generated transcript.]

Jeff Cranmer:

Welcome to a special edition of the BioCentury This Week podcast. I'm Jeff Cranmer, Executive Editor here at BioCentury. And today we bring you BioCentury's this week from Seoul where BioCentury's and BayHelix are hosting our 5th East-West Biopharma Summit. Today, uh, special guest, Ya-Ting Lei, Director of Business Development and Licensing at Merck Group from Germany, and Ruizhe Zhao, VP of Clinical Analytics China, at Caidya, are joining VP and Editor in Chief, Simone Fishburn and Josh Berlin, the illustrious Josh Berlin.

Simone Fishburn:

Oh, you got an illustrious this time its spreading.

Josh Berlin:

I've been called worse..

Simone Fishburn:

Yeah.

Jeff Cranmer:

I've noticed that

Simone Fishburn:

It gets worse.

Jeff Cranmer:

that Josh feels a little, you know,

Simone Fishburn:

Yeah.

Jeff Cranmer:

a little slighted when Stephen, you know, just keeps praise upon you, Simone, so.

Simone Fishburn:

Yeah, I get that a lot, yeah.

Jeff Cranmer:

We're going to talk about some of the key takeaways from three days of in-depth panel discussions, one-on-one meetings, presenting company presentations, networking, and some very, very bad karaoke, last night, of which I was perhaps the guiltiest party. Uh, and of course kimchi in its many delicious forms. Uh, Simone, what were your key takeaways?

Simone Fishburn:

Well, first of all, Jeff, I just have to ask 'cause I was not at the session with a karaoke last night, and will I be able to find it on TikTok?

Jeff Cranmer:

I'm afraid I've been sent several, uh, several videos already. I know someone.

Simone Fishburn:

Oh, excellent. This is now part of the record.

Jeff Cranmer:

Well, we always like to give props to Brian Denker, who's here. He's our, one of the men who makes our conferences go. And, uh, apparently someone's created a compilation of all the songs Brian sang. So hopefully, uh, that overshadows whatever horror I, uh, I did.

Simone Fishburn:

All right. Well, we'll be playing that on a future podcast, right Josh?

Josh Berlin:

I, I think so. And, uh, you know, we should give credit, I think to KoreaBio, one of our Regional Hosts.

Jeff Cranmer:

Indeed.

Josh Berlin:

They were certainly better at the karaoke, I think, than the BioCentury team.

Jeff Cranmer:

That's true.

Josh Berlin:

They have a little more practice, uh, Yeo and, and, and her colleagues sh shout out to Yeo, who, uh, got me to sing for the first time in, uh, since the last time I was in Seoul, actually. So, uh, well, let's, let's dig in here. We've got a lot of great stuff to talk about, Simone, uh, what's top of mind for you coming out of this week?

Simone Fishburn:

Well, I think probably top of mind, you gotta talk about energy, right? I think that there's just been a tremendous amount of energy here. I want to sort of draw, what we typically do is, of course, draw a few threads that have come in terms of take homes during this last few days. So I think if I go back to the scene setter, which sort of launched the conference. a few themes came up there that I think we could discuss and that sort of played out over the next few days. So in that scene setter, what we had done was we really wanted to focus on innovation in Asia. Outside of China. We spend a tremendous amount of time talking about China. Right? But you know, there's really a lot of question about, what about the other regions in Asia and what's going on here? And so we've done an analysis looking at deals in the last two years from biotechs in, the other, territories in Asia, and obviously may, maybe not obviously to everybody, but South Korea, really, by far is the most prolific, country after China in the region in terms of doing deals. But, you know, theme number one, Jeff, related to your panel, we'll come back to this I think later in the pod, is Japan had a much bigger showing there than I think people typically think of. I think everybody knows, and we'll talk about this, about the Strong, strong science in Japan. But the idea, and you've been writing about this, that it's rising as a biotech center is certainly something we're looking at. But let's just come back to, um, I'll just make a couple more comments here regarding South Korea, 'cause that is where we are. And, You know, the analysis, pointed to something that was gained, born out through the other conversations, and that's what I call an incredibly high innovation quotient. And so when we looked at the data and the deals, we saw something that we very rarely see, and that is among product deals. There were more first in class than not first in class, uh, potential, first in class, you know, assets in there. And when we looked and we dug in. the innovation, there's, there's people are taking target risk with completely new biology and people are taking modality risk, not in one sort of, you know, monolithic just antibody structures, but across the, across a range that were, there were eight deals with eight different modalities. And I think that what that taps into that I find very interesting is a need that, that is what South Korea and other regions of Asia need to do. They cannot play on me toos and me betters. And so they have to be leaning in into innovation. You might call it risk, but it's, it's actually the only path for them is to lean into target risk biology, risk, modality, risk. And so for me, that is a hallmark or brand that I think is starting to emerge, for sort of Korean biotech. I'm gonna stop there.

Jeff Cranmer:

Mm-hmm.

Simone Fishburn:

Right now, I, I wanted to raise one more thing and then, and then sort of springboard to you. One of the other things that we saw there that I think we've also talked about a lot is collaboration among Asia, well, biotechs within Asia countries. So maybe, you know, you can, you can pick it up from there.

Jeff Cranmer:

Yeah. Ruizhe, welcome to the program. I was so delighted to have you.

Luther (Ruizhe) Zhao:

Thank you.

Jeff Cranmer:

Um, I know there was a few things that really resonated with you. I, I don't know if you want to jump to Simone's question or, or just take it from there.

Luther (Ruizhe) Zhao:

Yeah. I, I think, uh, either working, in Asia out of China, but also globally because I'm working, as a biometrics function. So the topic of generating faster data in Asia interests me a lot. So, quote from one of our panelists yesterday that

Jeff Cranmer:

mm-hmm.

Luther (Ruizhe) Zhao:

Uh, there are only two types of speed is fast and faster.

Jeff Cranmer:

Oh, yeah.

Luther (Ruizhe) Zhao:

Yeah. Which, uh, enlightened me a lot. I think, but everyone, uh, working clinical trials as, uh, myself and I think Ya-Ting, that quality is still very important. The data should be reliable. And one new thing I think, um, being bring up in the session yesterday is that the data should be transferable and portable from one country to another, which is very important. Yeah.

Ya-Ting Lei:

Um, so I would like to give some, like, um, feedback on the, the, the intern. So the data transfer, uh, topic.

Jeff Cranmer:

Mm-hmm.

Ya-Ting Lei:

Right. So in the past few years, um, our team has been working like diligently on the, uh, Chinese project, but as you can imagine, uh, there's a strong mandate regarding the personal data policy and then I think it's very difficult to transfer the data across border. So it's always a pain point when we are performing due diligence process.

Jeff Cranmer:

Mm-hmm.

Ya-Ting Lei:

Right? And then if we don't see the data, then it's very difficult to see whether the data really have integrity issue or not. So I want to echo your points, right? The data has to be transferable, otherwise it's very difficult to check on spot.

Luther (Ruizhe) Zhao:

Yeah, yeah, true.

Ya-Ting Lei:

And then you need to fly in the colleagues sitting in the US or in Europe, like to fly into specific site. I think that's not very efficient.

Luther (Ruizhe) Zhao:

True. Uh, I think different countries make a lot of effort. For example, Australia is, uh, top one for the, uh, regulation approval. And for China, we had a lot of effort to improve the edge drug policies. But still we have a lot of, uh, room to discuss about the data privacy across different regions.

Jeff Cranmer:

Excellent. Lot, lot of love for Australia at, at the conference here. I know. I'm supposed to say something like, Ozzy, Ozzy, oy, oy, oy. Or is that, is that how y'all roll? Do we have any Australians here today?

Simone Fishburn:

Not bad. Not bad. Jeff. Not bad, Jeff.

Jeff Cranmer:

Well, I would have really leaned into it. Had I,

Simone Fishburn:

Well, we'll,

Jeff Cranmer:

anyway,

Simone Fishburn:

we'll practice that offline.

Jeff Cranmer:

We, we shall.

Simone Fishburn:

Yeah. So Josh, you know, we've talked a little bit about this. It's a theme at BioCentury, it's a theme in others of our conferences, and that is this real need for speed. I think Korea has been trying for many years aiming to become a center for clinical trials. It's now got a lot of competition from other countries. The U.K. is aiming to do that, we talked about that. Uh, in fact, Prague, the Eastern Europe where we're holding, uh, Bio€quity Europe. And so how are you looking at this, Josh, in terms of South Korea's ability to compete and how important a part of the South Korean kind of draw will that be?

Josh Berlin:

Yeah. Um, tha thanks for that, Simone. And you know, first off, wanted to just say thank you to our Korea host this week, uh, who have just been fantastic and really, welcoming. And, uh, you know, we've met so many, Korea biotech leaders, this week that, um, have, uh, stories to tell that we think will resonate, uh, across the global industry. But yeah, certainly the, the clinical trial, infrastructure here is world, class, you know, some of the, the KOLs and, and PIs here are really, uh, topnotch, you know, Simone, you had a, you know, I thought a great fireside chat, uh, yesterday with, professor, BC Cho of, uh, Yonsei University, you know, one of the top, oncology PIs in, in, in the world, really. And I do think folks are looking to China certainly for speed and, and, and for clinical trial data that helps to get de-risking faster. But there's also a lot of folks that are looking outside of China and, uh, I think certainly Australia, we've heard a lot, uh, today and, and this week. But Korea also I think has a, a major role to play there. You know, primarily known as a, I think a Phase II and Phase III hub for, uh, multi-regional clinical trials, but I know, uh, it's, it's something that a lot of folks are looking at now as another source to, to get data quicker to, to de-risk assets. And, you know, I don't know if Caidya, you know, is seeing the same thing more interest in, uh, in Korea trials as well.

Luther (Ruizhe) Zhao:

Yes, yes. We have office in Korea and of course we are working on, uh, either multiregional studies, local studies.

Josh Berlin:

Yeah.

Simone Fishburn:

Actually, can I just go back to, um, that very interesting and entertaining fire side chat with Professor Cho. One of the things that was interesting, although I think that there's some competitive spirit among the, uh, hospitals here, but that, that was rather nice. But in terms of collaboration. Because we, we think a lot about cross border. He really was talking about, I mean he's doing a lot of, uh, EGF receptor and, you know, other cancer research and he was talking about having collaborations with professors in Israel at, at Sheba Hospital. And I think that that is a really key thing for other places in Asia as well, but also Korea, to be creating these alliances around the world on the clinical trial structure. or on, on the clinical front. So that, that was extremely interesting for me, not something that I actually had anticipated hearing.

Jeff Cranmer:

Alliances, Simone, you're, you're not really keeping up with geopolitics. That's sort of a, a very, uh, last century kind of, uh, kind of thing. I'd like to, I'd like to turn to Ya-Ting now. Ya-Ting you mentioned, uh, mindset differences was one of the, the themes that really resonated with you here. Uh, can you expand on that a little bit?

Ya-Ting Lei:

Yeah. Happy to do so. Based on the session I went yesterday, I think it's a Capital, um, Market Showcase.

Jeff Cranmer:

Mm-hmm.

Ya-Ting Lei:

Uh, that was the second session I went yesterday. So the, uh, the panelists talk about the mindset differences between the Western and then uh, Asian investors. Right. So I think the comment was usually in the U.S. the investors are more sophisticated. Uh, we are seeing more, uh, healthcare specialists in, uh, the healthcare investment landscape. in contrast. For example, in Asia, we see there's a mix of generalists versus specialist. Right? And then if we are looking to the portfolio, they are investing in, and you can definitely see that like in many Asian VC or PE firms, um, even they are focused on healthcare, but they are like really investing in like hospitals, right? So this is very different from the investment thesis from the US century investors. Right. So I feel like that means the Asian investors could be more risk averse. And then I, I also like talked to an investor from Hong Kong, so he's also looking into the later stage asset, like what we are doing. Mm-hmm. Right. So for me, it's slightly eye-opening because you know, like if you want to invest earlier, it's riskier, but the rewarding, the reward might be higher, right? But if the, the assay is very de-risk, of course you need to pay premium for that, but the return, it's limited, right? So that's a, that surprised me, uh, slightly. And then, um, I think the second, uh, topic was around the post IPO obligations from the Hong Kong markets.

Jeff Cranmer:

Hmm.

Ya-Ting Lei:

Right. So when we talk to a lot of, uh, Chinese or Hong Kong companies, this is a topic that they often brought up because, they need to fulfill certain obligations from their investors or from, the government policies. So that means that we'll change how we structure the deal.

Jeff Cranmer:

Mm.

Ya-Ting Lei:

Right. So to be specific, a lot of time they, they will not give up the greater China rights. They want to keep it, so that means it make having a, a global deal very difficult because the China right will be out. Right. Will be cut out. And then also, if we dive into the details. They want to be the marketing, uh, authorization holder. That means they are able to book the sales so they can prove that they are creating the value, they are generating the revenue so they are able to fulfill those obligations. Right. And then as a BD person for a pharma, a lot of time we need to be flexible to change our deal structure. If we really interested in the assets.

Jeff Cranmer:

Mm-hmm. Ruizhe would you like to jump in there?

Luther (Ruizhe) Zhao:

Sure. Um, yeah, I do agree with that, what Ya-Ting has said about the mindset differences and also I heard from, uh, yesterday's session that there is a culture difference from the VC point of view. And one thing very important is to be in the culture, to do the VC investment in different regions and countries. And one word, inspires me a lot is that global diligence and local success, which is a very exciting statement.

Simone Fishburn:

Yeah, I think that, that's been a thread. I think that. The other angle on this thread, which is not really new, but still sort of had to be said, is that Korean companies at the other end, at the very early stages. They need to be thinking globally from the start, right? That there's, there's not gonna be a Korea market that is sufficient to justify it. And so, you know, even though we see China companies being incredibly global, they have a completely different dynamic that came actually through on the scene setter panel. And so this idea of thinking globally from the start is kind of interesting in light of the fact that when we looked at the deals, half of the deals are actually between, companies in different A parts of Asia. So it might be inside Korea or Korea, Japan. And I think in many cases that is part of the global strategy. You start with that, you create value. You, Maybe you're combining technologies to create an asset or something like that, and that's part of your strategy for going global rather than immediately. Trying to commercialize or, or find a partner in the West. So,

Jeff Cranmer:

And that was a, a a point on, uh, the Japan panel that we just had. So some of the folks in the audience here, uh, perhaps, heard that point. And, it was, uh, I think Dr. Fujimoto of the Shonan Health Innovation Park, he kind of spoke to the different mindsets, but how that can work toward a synergy. And, I suspect he kind of has a standup career separately because he seemed to get a lot of laughs when he talked about, how wonderfully Koreans with their aggressiveness could work with Japanese who, uh, perhaps not known for that. And, and how this could be leveraged with Korean biotechs going to Japan as maybe an initial, launching point or bringing the entrepreneurial spirit of Korea, uh, where we see many, many biotechs cropping up and, and sort of this. Big pharma mindset of Japan, which, after the us Japan's big pharma has brought most of the blockbuster drugs to the world.

Josh Berlin:

You know, I think the other part, that he mentioned, uh, was the number of Korean biotechs who have now set up shop in iPark. Uh, you know, we, uh, were out at, uh, BioJapan last year and had a chance to, to visit there. And it's a, it's a really impressive, uh, facility there. Huge, huge campus. Um, but the fact that there's now, you know, 8 or 10 Korean biotechs

Jeff Cranmer:

Yeah.

Josh Berlin:

set up in, in the park.

Jeff Cranmer:

Yeah. They, they said it was the, the, uh, we were, we were chatting at breakfast and he said it was the, largest, oh no, second largest freestanding building, in Japan after Narita airport, uh, which it's not bad.

Josh Berlin:

More, more biotechs, but less, uh, airplanes, I guess.

Simone Fishburn:

So I think, I think what's gonna be interesting to see is. You know, we, we tend to think in terms of, uh, hubs and ecosystems, in terms of bellwethers, right? We've talked about that in Europe. Looking at, you know, I know maybe Genmab is some bellwether there now, uh, obviously the China ecosystem has had a few bellwethers with BeOne and, I don't know, it's maybe Innovent one, something like that.

Jeff Cranmer:

Yeah. Becoming one. Yeah. Yeah. Legend.

Simone Fishburn:

Yeah. Legend. Uh, well, Legend is,

Jeff Cranmer:

Shout out to New Jersey baby.

Simone Fishburn:

Shout out to New Jersey, right?

Jeff Cranmer:

Yeah.

Simone Fishburn:

Legend. Okay, so we have a lot of a longstanding conversation, 'cause legend is actually headquartered in New Jersey. So do they get to call themselves Chinese, but everybody calls 'em Chinese, right?

Jeff Cranmer:

Yeah.

Simone Fishburn:

So, um, The main point here is what is the trajectory and what is the timeline for Korea to start to create, biotechs with that kind of gravitas, with that kind of ability and draw, that then what we've seen happen in these ecosystems is they do acquisitions or things get bought and they recycle the talent. And it, you know, Korea is, I I, I actually wanna take a quote from Billy Cho from, the scene setter panel, which he said, if you can solve for just two main bottlenecks, this could really be the beginning of a J curve, right? And his two bottlenecks were, of course, capital to value inflection. And the second thing was expertise in Korea for global clinical strategy. And so that might not be new when we think of lots of places around the world that have those challenges. But I think that that's a sort of path that we, he certainly expects to see Korea sort of enter that J curve.

Josh Berlin:

Yeah. And I, I think the other thing, I think that's spot on, um, both from, uh, you, Simone and Billy as well. Uh, but you know, we're also starting to see deals that are opening eyes, you know, certainly not at the volume of, of, of China, but maybe earlier days. But, you know, we had, um, Sang-hoon Lee , CEO, and Founder of ABL Bio on our Dealmaking panel. You know, he's had, uh, a couple of really, really big deals, uh, and, and a few other.

Simone Fishburn:

We got Orum Therapeutics here in the room.

Josh Berlin:

We got, we got SJ of Orum here. Um, we got a lot of our Korea, uh, biotech friends here. But I think the more, the more deal flow you see like that, the more it is uh, eyeopening in terms of numbers. It gives the whole ecosystem an opportunity to get more deals. It kind of validates the, the, the ecosystem. And I'd love, love to hear Merck's, you know, perspective on that, you know, in terms of, how much are you looking for deals now in, in, in Korea?

Ya-Ting Lei:

Um, so, um. as a BD person, we are scouting all the innovative assets across the Asia and globally. Right. And, but I wouldn't say, okay, we are only looking to assets from China or Korea only. So we look into everything but I have to say, every time when I come to Korea, I'm really. impressed by the novel therapies the company are producing earlier, they are trying to develop. Right. And then there are also a lot of emerging platforms. but you know, every pharma always have a mandate to look for specific things. A lot of time, maybe this time we don't see. a perfect asset, which can fit into our current portfolio, but I'm really looking forward to learn more partnerships with the Korean biotech and then really learning more about the ecosystem here. Right, because I think, um, I just talked to my sister this morning. She's sitting in Boston. She's a professor at Harvard. She says she has a lot of brilliant students coming from Korea, and I, I feel the same because I feel like the, the science, the. The science technology space here is so vibrant. Right. And then people are very open-minded here. At the same time, they're also very hardworking.

Jeff Cranmer:

Mm-hmm. Yeah.

Ya-Ting Lei:

So I'm sure Korea will be, you know, the next, uh, China. Yeah. You know, show people time.

Josh Berlin:

I, I thought, you know, one of the, to me, one of the highlights, uh, this week was the, um, the Regional Host Plenary that, uh, uh, KoreaBio uh, put together was moderated by Roche, but was looking at sort of next generation, biotech, leaders and, and companies here. Several of which I, I have to admit, I, you know, I hadn't really known of before. And, uh, you know, the fact that we had some young leaders here on stage who were very passionate about company building and their science, I mean, that's, that's really the future of, of what we're gonna see in Korea, I think.

Simone Fishburn:

I, I totally agree. Josh, can I, I, I just wanna add something and maybe you actually have some numbers. One of the things that was really interesting to me, you know, BioCentury was in China for a long time, telling, you know, this is where it's gonna be. And the rest of the world was like, oh wait, China, you know? And what we've been trying to say for this conference is, you know, don't be late to this party, as it were. And I certainly met during the last few days. Several VCs, some of whom from the west, sorry, from New York, from from the us, from other places who hadn't been to Korea before. This was all coming. Another person who told me they were gonna be coming back once a quarter, and so there is a sort of, I don't know if you have numbers on, you know, people from the west who are sort of starting to, to find this region, but it's certainly a, a don't sleep on Korea kind of thing.

Josh Berlin:

Yeah, I, I think that's exactly right. Uh, Simone, we were really happy to have some of our, uh, US and European VC friends out here this week. Uh, one, uh, comment I heard a couple of times, uh, maybe phrased differently, but a couple of times was, couple of the VCs being surprised at how sophisticated

Jeff Cranmer:

mm-hmm.

Josh Berlin:

the presentations were on our company track,

Jeff Cranmer:

Yeah.

Josh Berlin:

presenting company track, which, you know, Jeff, uh, was, was the one that selected many of those companies. But the fact that the Korean biotechs, they, you know, essentially they couldn't tell the difference between a Korea biotech presentation versus a US biotech presentation.

Jeff Cranmer:

Mm-hmm. and we had the, uh, the leaders of MNCs, based here in Korea on stage. who, uh, all of them said, their companies were just really investing more and more in Korea. so next big thing, it's gonna be fun to watch

Simone Fishburn:

the, the biotech version of K-pop. You know, it's gonna be like

Jeff Cranmer:

It's true. It's true.

Simone Fishburn:

Yeah.

Jeff Cranmer:

Um,

Simone Fishburn:

we have sort of KPop Demon Hunters kind of thing.

Jeff Cranmer:

KPop Demon Hunters has, um, taken the world. And, and I think someone said to, to you, Josh, uh, you know. K-pop took over the world and, and, K-biotech is gonna be even bigger. So,

Simone Fishburn:

Yeah.

Jeff Cranmer:

Uh, I told that to my Korean father-in-law, this morning, and he was, uh, he was pumped.

Simone Fishburn:

I, I, I hope we'll have the, like, the fashion to go with it. Do you think that'll be Yeah, I, that'd be quite good.

Jeff Cranmer:

I mean,

Luther (Ruizhe) Zhao:

Could be a fashion, could be a fashion.

Jeff Cranmer:

Right Ruizhe? Just right outside, there's, uh, all sorts of, uh, great Korean fashion right outside of our, uh, hotel here in Myeong-dong.

Simone Fishburn:

Well, if you say that, I will go and investigate that.

Jeff Cranmer:

Yeah, you, you really should. And, uh, while you're at it, uh, maybe stop at, uh, Olive Crush and, uh, pick up some, uh, you know, some, uh, makeup. And

Simone Fishburn:

You telling me what, what I need. You're telling

Jeff Cranmer:

No, no, I'm just saying that, uh,

Simone Fishburn:

This is not gonna end well, Jeff.

Jeff Cranmer:

Yeah, I'm just saying that if you just so happen to have, uh, you know, a man in your life who cared about you and wanted to take you shopping, uh, you know, it would be a nice way to spend some time after working so hard at this conference.

Simone Fishburn:

I agree.

Josh Berlin:

I agree. That's a decent recovery. Decent.

Jeff Cranmer:

Yeah. That's

Simone Fishburn:

Close one there.

Jeff Cranmer:

Yeah, I guess so. Well, alright, well I just wanna thank Ruizhe and Ya-Ting for joining us, here at the meeting here on the podcast. Josh as ever for, uh, leading us on our conferences team. And Simone, as always, you're, uh, sort of my partner in crime on the podcast and, uh, a big shout out to McKinsey for their wonderful presentation today. And, BayHelix for partnering with us on Get another meeting. And of course, our Korean collaborators on this meeting. you've been listening to the BioCentury This Week podcast, from Seoul, South Korea. Thanks for tuning in and we will catch you next time.

Josh Berlin:

Thanks, Jeff.

Luther (Ruizhe) Zhao:

Thank you.

Ya-Ting Lei:

Thank you.

Jeff Cranmer:

Alright. Thank you so much. Kendall Square Orchestra provides the music for BioCentury this week. The group connects science and technology professionals and other members of the greater Boston community to collaborate, innovate, and inspire through music, while supporting causes related to healthcare and education.

Podcasts we love

Check out these other fine podcasts recommended by us, not an algorithm.